Serving Overlooked Patients^SM

Azurity Pharmaceuticals is a privately held company committed to delivering innovative, high-quality medicines for overlooked patients. Azurity’s global footprint is over 50 countries, with a diversified portfolio of 50+ medicines spanning 10 dosage forms and 10 key therapeutic areas. Powered by its Next-Gen Commercial Model, Azurity leverages data, analytics, and AI-driven digital tools to enhance market reach and stakeholder engagement. Our medicines have benefited millions of people.

PRODUCT ANNOUNCEMENT

NOW AVAILABLE

ferabright Logo

Learn about Ferabright^TM

Click for Full Prescribing Information,
including Indication, BOXED WARNING, and Important Safety Information.

PRODUCT ANNOUNCEMENT

Xifyrm Logo

Learn about Javadin^TM

Click for Full Prescribing Information, including Indication and Additional Safety Information.

PRODUCT ANNOUNCEMENT

NOW AVAILABLE

ferabright Logo

Learn about Ferabright^TM

Click for Full Prescribing Information, including Indication, BOXED WARNING, and Important Safety Information.

PRODUCT ANNOUNCEMENT

Xifyrm Logo

Learn about Javadin^TM

Click for Full Prescribing Information, including Indication and Additional Safety Information.

OUR PRODUCTS

Azurity offers an ever expanding portfolio of products targeting key therapeutic areas.

Explore all products

News & Events

ACA Pharma and Azurity Pharmaceuticals Announce Approval of Feraheme^® and Ferabright^™ in Macau

May 21, 2026

NEW YORK, NY May 21, 2026 — ACA Pharma and Azurity Pharmaceuticals announced that Feraheme® and Ferabright™ have each received regulatory approval in Macau, marking an important step in expanding access to ferumoxytol-based products across key markets in Asia. These approvals reflect the continued collaboration between ACA Pharma and Azurity to advance regulatory pathways and improve patient access throughout Greater China.

Azurity Pharmaceuticals Announces the Availability of ARYNTA^TM (lisdexamfetamine dimesylate) Oral Solution, CII

Apr 6, 2026

Woburn, MA — April 6, 2026 — Azurity Pharmaceuticals, Inc. announced that ARYNTA^TM (lisdexamfetamine dimesylate) Oral Solution is now available in the United States for treating ADHD in adults and pediatric patients 6 years and older. Arynta, a ready-to-use lisdexamfetamine oral solution that may be stored at room temperature between 68°F to 77°F (20°C to 25°C),¹ received FDA approval in June 2025.

Name	Provider	Purpose	Expiration
ARRAffinity	snazzymaps.com (third-party cookie)	This is an Azure cookie. It keeps track of connecting users by giving them a so-called cookie. This ensures the link between clients and the server they connect to for the entirety of their session.	Session
ARRAffinitySameSite	snazzymaps.com (third-party cookie)	This is an Azure cookie. This cookie is used for load balancing and to distribute traffic to the Website on several servers in order to optimize response times.	Session
wordpress_test_cookie	Azurity (first-party cookie)	Used on websites built with Wordpress. This cookie tests whether or not the browser has cookies enabled.	Session

Name	Provider	Purpose	Expiration
_clck	Azurity (first-party cookie)	This cookie is used by Microsoft Clarity. It persists the Clarity User ID and preferences, unique to that site is attributed to the same user ID.	1 year
_ga	Azurity (first-party cookie)	This cookie is associated with Google Universal Analytics - which is a significant update to Google's more commonly used analytics service. This cookie is used to distinguish unique users by assigning a randomly generated number as a client identifier. It is included in each page request in a site and used to calculate visitor, session and campaign data for the sites analytics reports.	14 months
_ga_xxxxxxxxxx	Azurity (first-party cookie)	This cookie is used to generate statistical data on how the visitor uses our services.	1 year
_gat_UA-nnnnnnn-nn	Azurity (first-party cookie)	Google Analytics sets this cookie for user behavior tracking.	Less than 1 day
_gclxxxx	Azurity (first-party cookie)	This cookie is a Google conversion tracking cookie used in connection with Google Analytics.	89 days
_gid	Azurity (first-party cookie)	Installed by Google Analytics, this cookie stores information on how visitors use a website while also creating an analytics report of the website’s performance. It stores and updates a unique value for each page visited. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.	1 day
itsec-hb-login-*	Azurity (first-party cookie)	This cookie is placed by iThemes Security. It is used to provide the hiding of the WordPress login URL.	Less than 1 day
SM	Azurity (first-party cookie)	This cookie is used in synchronizing the MUID across Microsoft domains.	Session

Name	Provider	Purpose	Expiration
ANONCHK	Microsoft Clarity (third-party cookie)	This cookie indicates whether MUID is transferred to ANID, a cookie used for advertising. Clarity doesn't use ANID and so this is always set to 0.	Less than 1 day
ar_debug	doubleclick.net (third-party cookie)	This cookie is used by DoubleClick for advertising that Google serves across the Internet. Also used to store and track conversations.	30 days
CLID	Microsoft Clarity (third-party cookie)	This cookie identifies the first-time Clarity saw this user on any site using Clarity.	1 year
_clsk	Azurity (first-party cookie)	This cookie is associated with Microsoft Clarity. This cookie is used to store and connect multiple page views by a user into a single Clarity session recording.	1 day
IDE	doubleclick.net (third-party cookie)	This cookie is used by DoubleClick for advertising that Google serves across the Internet.	2 years
MR	Microsoft Bing (third-party cookie)	This cookie is used to synchronize the ID across many different Microsoft domains to enable user tracking.	6 days
MR	Microsoft Clarity (third-party cookie)	This cookie is used to synchronize the ID across many different Microsoft domains to enable user tracking.	6 days
MUID	Microsoft Bing (third-party cookie)	This cookie is set to recognize unique web browsers visiting Microsoft sites. This cookie is used for advertising and site analytics.	1 year
MUID	Microsoft Clarity (third-party cookie)	This cookie is set to recognize unique web browsers visiting Microsoft sites. This cookie is used for advertising and site analytics.	1 year
receive-cookie-deprecation	doubleclick.net (third-party cookie)	Part of a Google Chrome experiment to identify if a user's browser is in specific test groups within Chrome’s Privacy Sandbox initiative. Websites must opt-in to use it. The cookie tracks group participation (e.g., "example_label_1") and it will be discontinued after the experiment.	180 days
SRM_B	Microsoft Bing (third-party cookie)	This cookie identifies unique web browsers visiting Microsoft sites. These cookies are used for advertising, site analytics, and other operational purposes.	1 year
test_cookie	doubleclick.net (third-party cookie)	This cookie is used by DoubleClick for advertising that Google serves across the Internet.	Less than 1 day

Serving Overlooked Patients^SM

PRODUCT ANNOUNCEMENT

NOW AVAILABLE

PRODUCT ANNOUNCEMENT

PRODUCT ANNOUNCEMENT

NOW AVAILABLE

PRODUCT ANNOUNCEMENT

OUR PRODUCTS

News & Events

ACA Pharma and Azurity Pharmaceuticals Announce Approval of Feraheme^® and Ferabright^™ in Macau

Azurity Pharmaceuticals Announces the Availability of ARYNTA^TM (lisdexamfetamine dimesylate) Oral Solution, CII

Company

Products

Resources

You are now leaving the azurity.com website. / Vous allez quitter le site azurity.com

PRODUCT ANNOUNCEMENT

Learn More About AZURITY^®

Learn more about how AZURITY may benefit your patients.

Terms and conditions

Serving Overlooked PatientsSM

PRODUCT ANNOUNCEMENT

NOW AVAILABLE

PRODUCT ANNOUNCEMENT

PRODUCT ANNOUNCEMENT

NOW AVAILABLE

PRODUCT ANNOUNCEMENT

OUR PRODUCTS

News & Events

ACA Pharma and Azurity Pharmaceuticals Announce Approval of Feraheme® and Ferabright™ in Macau

Azurity Pharmaceuticals Announces the Availability of ARYNTATM (lisdexamfetamine dimesylate) Oral Solution, CII

Serving Overlooked Patients^SM

ACA Pharma and Azurity Pharmaceuticals Announce Approval of Feraheme^® and Ferabright^™ in Macau

Azurity Pharmaceuticals Announces the Availability of ARYNTA^TM (lisdexamfetamine dimesylate) Oral Solution, CII